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1.

Introduction
In 1979, Archibald Cochrane, a Scottish doctor, proposed: "It is surely a great criticism of our profession that we have not organised a critical summary, by specialty or subspecialty, adapted periodically, of all relevant randomised controlled trials" [1] . Cochrane was one of the founding fathers of evidence-based medicine. He highlighted and advocated the importance of critically summarising the findings of research studies and was passionate about this cause. He designated the systematic review (SR) as a method providing such a summary [1] . Cochrane's vision ultimately led to the development of the Cochrane Collaboration in 1993.
The findings of SRs and meta-analyses (MAs) are used for clinical decision making and are integral in developing sound clinical practice guidelines and recommendations. The European Association of Urology (EAU) has committed increasing resources into the development of high quality clinical guidelines based on such SRs and MAs [2] [3] [4] . The Guidelines Office has completed 21 SRs and 32 reviews are ongoing. These high quality systematic reviews are used for making guideline recommendations [5] . Supplementary Table 1 summarises the Guideline recommendation(s) underpinned by the selected SRs conducted under the auspices of the EAU Guidelines Office. In this paper, we have summarised the process of conducting SRs under the auspices of the EAU Guidelines Office. The process is also graphically illustrated in Figure 1 .
2.
Evidence acquisition
What is a randomised controlled trial?
A randomised controlled trial (RCT) is a type of study in which participants are randomly assigned to two or more groups in order to assess interventions. A well designed RCT is adequately powered and follows the principles and recommendations of the CONSORT statement [6] .
What is a SR?
A SR identifies, selects, synthesises, and appraises studies that meet prespecified inclusion criteria to answer a research question. The process involves explicit methods and the findings should be reproducible. A SR not only identifies, quality. A SR not only identifies, evaluates, and summarises the best available evidence, but also the gaps to be targeted by future studies.
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Conclusions: SRs and MAs are integral in developing sound clinical practice guidelines and recommendations. Patient summary: Clinical practice guidelines should be evidence based, and systematic reviews and meta-analyses are essential in their production. We have discussed the key steps of conducting systematic reviews and meta-analyses in this paper. © 2017 Published by Elsevier B.V. on behalf of European Association of Urology.
evaluates, and summarises the best available evidence, but also the gaps to be targeted by future studies [7] .
2.3.
What is a MA?
In SRs, data for particular outcomes in individual RCTs may be combined statistically in a MA to increase power when the studies are similar enough [7] . A MA may thus be able to answer a clinical question which is unanswerable by individual studies due to inadequate power. A MA should not be done outside of the SR setting because it is unlikely that all relevant trials will have been identified and therefore a biased or misleading pooled estimate may result. The term MA was coined by an American statistician, Gene Glass [8] .
What is a traditional review?
A traditional review is usually written by an expert and provides a summary or an overview of a topic. Unlike a SR, the topic of a traditional review is often broad and less precisely defined. The methods used to conduct traditional reviews are not standardised. The search strategy is usually not stated, the review is confined to well-known articles [9] , and the author's personal beliefs may influence the overall conclusion [10] . If a MA is attempted in this situation, an exaggerated and spuriously precise estimate may be obtained and treated with greater credibility than it is due. The main features of SRs are covered throughout this report and the key differences between a SR and traditional review are summarised in Table 1 . When conducting a SR, the essential first step is to formulate a clear and answerable research question. This clarifies the objectives and the study inclusion and exclusion criteria. A straightforward way to do this is to break the question down into constituent parts using the PICO framework, which stands for Participants, Intervention, Comparator, and Outcomes [11] .
It is necessary to be transparent and explicit about which populations, intervention, comparator, and outcomes are to be included or excluded. This is important for not only designing the search strategy but is also helpful for systematic reviewers who do not necessarily have in-depth clinical knowledge on the topic. Furthermore, it serves as a blueprint to inform study screening and data extraction. To illustrate: "Should I perform partial nephrectomy on a patient with kidney cancer?" is a meaningful question, particularly for urologists. However, it is vague and not informative for deciding which studies should be included. A more scientific way for phrasing this question is: "In patients with localised renal cell carcinoma (P), how effective is partial nephrectomy (I), when compared with radical nephrectomy (C), in improving overall survival (O)?"
Of course, more clinically or methodologically justifiable detail will need to be provided to define limits on age, disease stage, which approaches to partial and radical nephrectomy are included, which other (secondary) outcomes should be included, and search date cut-offs. The types of study designs to be included should be specified. Cochrane SRs are traditionally confined to evidence from RCTs. However, it is not always ethical to randomise participants for comparing interventions and observational studies play a crucial role in this scenario.
SRs should be protocol driven and prospectively registered in a database, such as PROSPERO [12] or the Cochrane Library, to help counter publication bias and selective outcome reporting by giving a permanent record of the a priori methods. PROSPERO is a database maintained by the University of York. PROSPERO provides a free registration and publication of systematic review protocols and is available at the following link: https://www.crd.york.ac.uk/ PROSPERO/. Registration of protocols also means that others can see if a review is currently underway and work is not duplicated. Crucially, in addition to the PICO elements, a protocol outlines what actions will be taken in which circumstances, such as how particular types of data will be handled in the analyses, the conditions under which MAs or narrative synthesis will be undertaken, which subgroups will be analysed, and how risk of bias (RoB) will be assessed. 
Evidence synthesis
Literature search
Extensive literature search lays the foundation for evidence synthesis. With increasing numbers of published research reports and numerous bibliographic databases, it is challenging to efficiently identify relevant studies, especially when research topics are complex and study designs are not limited to RCTs. Conducting a literature search to identify relevant reports from databases and other resources requires rigorous search techniques. When designing searches, high sensitivity and high specificity should be aimed for. However, no search strategy is 100% perfect; high sensitivity may result in a huge number of irrelevant records and there is always a trade-off. It is advisable to involve an information scientist for designing search strategies.
Literature searches for SRs should involve at least two bibliographic databases and be as extensive as possible in order to identify all relevant studies and increase the generalisability of the results. According to Methodological Expectations for Cochrane Intervention Reviews, Cochrane Central Register of Controlled Trials, MEDLINE, (and EMBASE and Cochrane Review Group's Specialized Register when available) are the minimum databases to be searched for a Cochrane SR [13] . Most published SRs now search at least MEDLINE, EMBASE, and Cochrane library databases. Databases relevant to the topic of the review (eg, CINAHL for nursing-related topics), national and regional databases, and subject-specific databases should also be considered. Trials registers such as ClinicalTrials.gov, the World Health Organisation International Clinical Trials Registry Platform portal, and other sources (eg, pharmaceutical industry and regulatory agencies websites) should be searched for unpublished and ongoing studies. Other sources include dissertations, theses, conference abstracts and proceedings, and grey literature (information produced in electronic and print formats not controlled by commercial publishing) databases. Searching the bibliographies of identified relevant studies and previous SRs on the same topic is a good approach for reducing the chance of missing relevant studies. Study authors and organisations should be contacted for missing information on unpublished or ongoing studies [7, 13] .
Content experts are very important in designing advanced search strategies [7] . By working closely with information specialists, they can assist with identifying search concepts, and suggest keywords as well as key references, while revising and improving preliminary searches. Too many different search concepts should be avoided. Sometimes, some concepts (eg, outcomes) may not be well described in the title or abstract of an article and are often not well indexed with controlled vocabulary terms; it might be better to search only for the population and intervention. However, a broad range and wide variety of search terms should be combined with "OR" within each concept. Both free-text words (including spelling variants, synonyms, related terms, opposites, plurals, acronyms, truncations, wildcards, and proximity operators) and appropriate subject headings should be used (eg, MeSH and EMTREE). Ensure the Boolean operators "AND," "NOT," and "OR" are used correctly. An example of a search strategy, along with an explanation, is presented in Figure 2 . Strategies must be translated for every database and each interface (eg, PUBMED and OvidSP are two different interfaces for the same database MEDLINE).
Specially designed high sensitivity and tested filters can be used when appropriate. There is no need to use an RCT filter when searching Cochrane Central Register of Controlled Trials because all the records are thoroughly and correctly indexed. Applying a publication date, publication format, or language restrictions in the search strategy should be justified and included in the report [7] .
The search strategy should be documented and reported transparently in the protocol and in the review. It is necessary to report the sources searched (databases and interfaces), dates and limits, and the numbers found from each source [14, 15] . Key search terms can be reported in the methods section. The full search strategies for one or more electronic databases can be submitted as an appendix and published as supplementary files available online to readers.
Abstract and full-text screening
After the literature search has been conducted, the list of retrieved abstracts is screened for studies that may be eligible for inclusion. Abstract screening is performed using an a-priori developed study screening form. This form contains the inclusion and exclusion criteria for each PICO element as reported in the study protocol. Following this form will lead to the decision whether to exclude or include the abstract. In case no decision can be made based on the information in the abstract, it will be marked as "unclear." Unclear abstracts are included at this stage, as it requires fulltext retrieval and review to make the final decision. Abstract screening must be performed independently by (at least) two reviewers. The combined results will subsequently be reviewed for disagreements, and a third independent reviewer can be consulted for resolving conflicts.
Full-text screening follows the same principles as abstract screening. A difference, however, is that full-text papers cannot be marked as "unclear" but require a definitive decision whether to include or exclude the study. Also, for excluded full-text papers, reviewers must keep track of the reason for exclusion. Upon completion, the final number of included and excluded studies (with the reason for exclusion) is reported in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram as illustrated in Figure 3. 
3.3.
Data extraction from included studies
One of the most important and time-consuming parts of a SR is data extraction. Data are extracted independently by two reviewers and any disagreements are resolved by discussion or arbitration by a third reviewer [16] . Table 2 summarises the key information that should be extracted from the studies included in a SR. Each review question is unique and therefore requires development of a separate form. A pilot tested electronic or paper version of the data extraction form includes entries for study characteristics along with relevant results and RoB assessment. The data extraction form should first be piloted on two to three studies.
The setting and timing of the study, participants, and disease characteristics (such as age, sex, comorbidities, diagnostic criteria, staging, and prognostic factors) that may influence intervention effects or external validity should be collected. Relevant information on interventions include surgical techniques, drug doses and frequency, or routes of delivery. It is important to clearly predecide the outcome measures that will be collected in terms of their definition (eg, measurement method, scale, and threshold), timing, and unit(s) of measurement. This is crucial as many outcomes may be reported using multiple definitions (eg, biochemical recurrence after radical prostatectomy), measurement scales (eg, multiple urinary symptom questionnaires to access the severity of urinary incontinence), measurement method (eg, healthy parenchymal volume loss after partial nephrectomy measured by computed tomography volumetric analysis or estimated by surgeon), or different points in time (eg, cancer-specific survival at 1 yr, 5 yr, and 10 yr). Standardised sets of outcomes, known as "core outcome sets" represent the minimum that should be measured and reported in all clinical trials of a specific condition making it easier for the results of trials to be combined [17] . The numerical data required for MA are not always available and sometimes other statistics or graphical information can be collected and converted into the required format.
RoB assessment
Biases in studies included in a SR can lead to either an overestimation or an underestimation of true intervention effect size, resulting in heterogeneity in outcome between studies.
RCTs
In SRs of RCTs, the RoB in each study is assessed for each outcome using the domains (judged as either low, high, or unclear) in the Cochrane Collaboration's RoB Tool [7, 18] :
Selection bias, which includes random sequence generation bias and allocation concealment bias. Performance bias due to knowledge of the allocated intervention by study personnel and participants.
[ 
( F i g . _ 2 ) T D $ F I G ]
Detection bias in assessing the outcome due to knowledge of the allocated intervention. Attrition bias due to incomplete data and exclusion from analyses.
Reporting bias due to selective outcome reporting.
Other sources of bias.
RevMan is then used to create a RoB summary graph to visually illustrate the RoB (low, high, or unclear) for each domain in each study [19] . A draft version of a revised tool to assess the RoB in RCTs (RoB 2.0) has recently been proposed [20] . 
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Nonrandomised comparative studies
Potential biases are greater in nonrandomised comparative studies (NRCS) than for RCTs due to the high risk of confounding. NRCS are thus always considered to be at high risk of selection bias.
In addition to assessing the above domains for RCTs, a maximum of the five most important confounders should be prespecified. For each outcome, an assessment is made of: (1) whether the confounder was considered, (2) whether its distribution was balanced, and if not then (3) whether it was controlled for in the analysis.
This information is used to reach an overall decision about the RoB for each confounder and each outcome. The RoB summary graph can also include the additional confounder information.
Recently, ROBINS-I, a tool for assessing risk of bias in nonrandomised studies of interventions has been published. This tool is not yet tested within the EAU [[ 1 1 _ T D $ D I F F ] 22].
Single arm studies
In SRs of single arm case series, five aspects are considered:
1. Was there an a priori protocol? 2. Was the total population included or were study participants selected consecutively? 3. Was outcome data complete for all participants and any missing data adequately explained/unlikely to be related to the outcome? 4. Were all prespecified outcomes of interest and expected outcomes reported? 5. Were primary benefit and harm outcomes appropriately measured?
If the answer to all five questions is "yes," the study is at "low" RoB. If the answer to any question is "no," the study is at "high" RoB.
QUADAS-2 is used for assessing RoB in diagnostic test accuracy SRs [[ 1 2 _ T D $ D I F F ] 23], while QUIPS is used for prognostic factor SRs [[ 1 3 _ T D $ D I F F ] 24].
RoB assessment process
Two reviewers independently assess the RoB in each study when extracting data. A third reviewer acts as an arbitrator. If the RoB is unclear in any domain, an attempt is made to obtain the study protocol or to contact the study authors. RoB summary graphs are created with separate graphs for each of the three different study types. Biases are described in the SR report, emphasising areas of concern and the possible effect of bias in interpreting the results [18] . However, before meta-analysing data, a detailed assessment of the included studies is crucial to decide whether a MA of the results is not only feasible but also sensible. First, the internal validity and precision of the included studies will directly impact the quality of a MA. If the included Review author comments CI = confidence interval; FN = false negative; FP = false positive; HR = hazard ratio; ID = identification; IPSS = International Prostate Symptom Score; RCT = randomised controlled trial; RoB = risk of bias; SD = standard deviation; TN = true negative; TP = true positive. a For comparative effectiveness of interventions systematic reviews. b For diagnostic test accuracy systematic reviews. c For prognostic factor systematic reviews.
studies are biased, underpowered, or the individuals estimates inconsistent, then performing a MA can potentially give a spuriously precise and often meaningless summary statistic. One should take into account that the studies included in a SR will inevitably differ. Despite clearly defined eligibility criteria, differences in the included studies will exist with regards to natural variation in the populations and fidelity to the interventions. Those variations are known as heterogeneity [[ 1 6 _ T D $ D I F F ] 27]. There are three main types of heterogeneity: (1) clinical heterogeneity, which refers to variations in the populations, interventions or the way in which the outcomes were assessed, (2) methodological heterogeneity, which refers to differences in study design and reporting biases, (3) and statistical heterogeneity, which refers to variability in treatment effects due to the way the data are analysed and reported in each study.
There are several ways to investigate heterogeneity. First, heterogeneity can be assessed by visual inspection of the forest plots. Poor overlap among confidence intervals may indicate statistical heterogeneity. The chi-square Q statistic assesses the degree to which the individual study estimates of effect size differ from the overall estimate, while the I 2 statistic is an estimate of the percent of variation attributable to heterogeneity, that is, the ratio of true heterogeneity to total observed variation [7, 27, 28] .
is considered substantial. MA and the estimation of an overall summary effect in the presence of significant heterogeneity may be misleading, but several options can be considered in this scenario. Some heterogeneity may be explained by the intervention having different effects in, for example, older populations or at higher doses of a drug. In such instances, the stratification of studies according to their characteristics or subgroup analyses in specific patient populations may be done to explore heterogeneity or to try to answer specific questions; however, this may not . They are also more likely to be published quickly, in more than one place, in English, in high impact, indexed journals, and cited by others [7] . Funnel plots, which plot the effect estimate of individual studies against the size of the study, may be used to identify the publication bias but these should only be used when there are at least 10 studies in the MA.
In circumstances where there is too much heterogeneity, or when a review has included NRCS, it is more appropriate to conduct a "narrative synthesis" 33, 34] . This is a theory driven and iterative approach for summarising and imposing structure on the results of the included studies. Four main stages are involved:
1. Develop a theory of how the intervention works, why, and for whom. Essential activities include tabulating and describing the key baseline characteristics and results of individual studies. Then studies with similar populations, intervention, and outcome measurement characteristics can be grouped together and then further grouped with regards to the direction and magnitude of the results. The results may then be interpreted critically with regards to the theory, considering also the RoB and potential confounders within and across the included studies to make statements about the quality of the evidence about the intervention. Figure 4 illustrates a decision flow diagram when to meta-analyse data or to use narrative synthesis. . The final quality assessment, which applies to the body of evidence (all studies included in the SR) is reported as one of four possible levels: high, moderate, low, or very low. Foremost is that RCTs start out as high quality and that nonrandomised (observational) studies start out as low quality. According to GRADE, there are five factors which can affect overall evidence quality which starts out high in a negative way, and three factors which can affect quality which starts low in a positive way
Starting at potentially high quality, RCTs are susceptible to certain biases which, when present, can raise doubt in the study findings. Once summarised, these inherent study elements inform the overall RoB of all the studies included in the analysis. This overall study "RoB" is the first of the five "negative" factors used in GRADE to assess the overall quality of the evidence. Next are items which assess how the overall evidence is represented and balanced. "Inconsistency" examines the direction of different study results. For example, if one study shows an intervention is helpful while another does not, they are inconsistent. "Indirectness" examines the details of exactly what is compared in the various studies being reviewed. If studies use different intervention methods, they may be indirectly comparing results. "Imprecision" examines the margin of potential error within all combined studies. All of these factors may raise doubts about the validity of the combined data, especially when trying to use it for a recommendation. If observational studies are incorporated in a SR, inherent study bias is already assumed and the overall evidence quality starts out as "low." However, if the combined effect size of the outcome is undeniable ("large" > 50%, "very large" > 75%), if there is an obvious dose response seen, or if there is evidence that the plausible confounders would diminish the demonstrated effect, the quality of this evidence can actually be raised. Evidence from observational studies that has been downgraded for any reason (as explained above) should not be upgraded. The process of assessing the quality of evidence is summarised in Figure 5 . Ultimately this process strives to be structured, systematic, and transparent.
3.7.
Incorporation of systematic review results in guidelines
The aim of the EAU Guidelines is to assist practicing clinicians in making informed decisions in different clinical situations, taking the highest quality scientific data, their patient's personal circumstances, values, and preferences into account. The development of the guidelines is a core activity of the EAU as part of their educational efforts and the available guidelines cover most of the urological field. A transparent production process and continuous updating are assured to ensure that these guideline documents are, and remain, of high value to their users. High quality SRs are a superb source of data when composing clinical guidelines. The EAU Guideline Office made a major step forward when deciding not only to use such SRs for the guidelines, but to also perform their own SRs based on PICO questions identified and defined by the expert panels. The SRs are performed in a standardised manner, following Cochrane methodology, with inclusion of expert urologists, associates, methodologists, statisticians, and medical librarians. The results are published in peer-reviewed journals and are included in the annual updates of the specific guideline. 
